We have recently reported that @entity5 levels of @entity1594 , a key mediator of transforming growth factor-beta superfamily signaling, can predict the probability of recurrence in @entity1 with @entity14 who had surgery as the only form of treatment. However, standard treatment for @entity14 @entity1 currently involves the administration of @entity1487 ( @entity1487 )-based adjuvant chemotherapy after surgery. Approximately 30% to 40% of these @entity1 present with recurrence and die within 5 years, and there is great need for markers capable of predicting poor prognosis after the combined surgery/adjuvant treatment. In this study, we evaluate the prognostic value of @entity1594 in @entity1 treated with surgery and @entity1487 -based adjuvant therapy. We used immunohistochemistry and quantitative real-time reverse transcription-PCR to measure the levels of @entity1594 protein and mRNA expression in the @entity5 and a number of lymph node metastases from a series of 75 @entity14 @entity1 with at least 6 years of follow-up. @entity1 with @entity5 expressing low levels of @entity1594 protein or mRNA showed significantly shorted disease-free and overall survival than @entity1 with high @entity5 levels of @entity1594 . The median survival of @entity1 with low @entity1594 protein or mRNA @entity5 levels was 1.4 and 1.2 years, respectively, whereas @entity1 with high @entity1594 @entity5 level had a median survival of >9.3 years. In addition, the protein and mRNA levels of @entity1594 in lymph node metastases was significantly lower than in @entity5 (P = 0.006). In contrast, @entity74 in chromosome 18q21 was of no prognostic significance in these @entity1 . In conclusion, low @entity1594 @entity5 levels identified a subset of @entity1 with poor prognosis following surgery and @entity1487 -based adjuvant therapy; therefore, these @entity1 could be good candidates to receive combined treatment with additional chemotherapeutic agents such as @entity2600 and/or @entity901 .

@entity1594 levels and response to XXXX in @entity14 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['CPT-11'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'low tumor', 'tumors'] @entity74 :: ('MESH:D030342', 'Disease') :: ['allelic imbalance'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Dukes C colorectal cancer'] @entity1594 :: ('4089', 'Gene') :: ['SMAD4'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']
